OSTEOCALCIN PROMOTER-BASED TOXIC GENE THERAPY

Abstract: A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered directly or systemically (intravascularly) to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

Description: TTT E OF THE INVENTION OSTEOCALCIN PROMOTER-BASED TOXIC GENE THERAPY BACKGROUND OF THE INVENTION Field of the Invention This invention pertains to the systemic administration of an active agent, a recombinant gene comprising an adenovirus (Ad) which contains an osteocalcin promoter (OC) which drives the expression of thymidine kinase (TK). The agent itself is fully disclosed in the parent application. This invention pertains to the discovery that Ad-OC-TK may be administered systemically, both to treat tumors, and to treat certain benign conditions such as benign prostatic hypertrophy and certain forms of arteriosclerosis. Background of Related Work Toxic gene therapy for the treatment of cancer continues to gain prominence in basic research, but remains limited in clinical application because of an inability to deliver the toxic gene to the tumor cells with specificity. Many vectors (e.g. retroviruses, retroviral producing cells, adenoviruses, liposomes, and others) can deliver genes (therapeutic or toxic) to target cells. Localized delivery and restricted gene expression to the primary tumor have been accomplished via direct injection of therapeutic viruses in animal models 1"4 and clinical trails. 5 ' 6 This approach is not feasible for the treatment of metastatic disease because of the presence of multiple lesions that would each require separate injection and manipulation. Therefore, alternative approaches to the treatment of metastatic disease with gene therapy must be developed. Systemic delivery of therapeutic genes is attractive for targeting metastatic disease, pulmonary metastases in particular. Because the pulmonary vascular system would be the first encountered, the adenovirus would be trapped in the lung parenchyma, allowing for higher infectivity. Lesoon-Wood et al.. 7 reported the systemic delivery of wild type p53 complexed with liposomes, targeting the p53 mutated breast cancer cell line (MDA- MB435), inhibiting primary tumor growth by 60% , and decreasing pulmonary metastases in nude mice. Vile et al. 8 demonstrated inhibition of B-16 melanoma pulmonary metastases in syngeneic immunocompetent mice by a systemic delivery of retrovirus using a tyrosinase promoter to drive the expression of the toxic gene thymidine kinase (TK) gene. Compared to liposome or retrovirus, adenovirus has several advantages in a systemic delivery strategy, such as its high infectivity in vivo and production techniques that can achieve high viral titers. However, Brand et al. 9 recently reported that systemic administration of adenovirus containing TK under the control of a universal promoter (CMV) supplemented with ganciclovir treatment induced severe hepatotoxic effects. This study suggested that restriction of toxic gene (TK) expression by tissue specific promoter may be necessary prior to the consideration of systemic adenoviral vector delivery. Moreover, the tissue-specific promoter should limit the toxic gene expression in normal tissues so it can be applied in higher doses than the universal promoter-based toxic gene therapy for more effective treatment of metastatic diseases. To study the potential therapeutic efficacy of systemic cancer gene therapy for the treatment of pulmonary metastases, osteosarcoma is an attractive model because a significant number of these patients eventually develop lung metastasis. Initially, surgical resection of the primary lesion and adjunctive chemotherapy are the mainstay of today's therapy. For the 20% that present with metastatic disease, 80% will require additional therapy for relapse; while of the 80% that present with local disease, 35% will require additional therapy for relapse after surgery and adjunctive chemotherapy. 10 Therefore, 44% of patients diagnosed with osteosarcoma will fail conventional first line therapy. Patients developing recurrent disease usually have a poor prognosis, dying within one year of the development of metastatic disease. 11"14 New therapeutic approaches that can be applied either separately or in conjunction with current modalities in treating osteosarcoma pulmonary metastases are needed. The osteocalcin promoter (OC) has been shown to be highly effective in directing the transcription of reporter genes in both rat and human osteosarcoma cell lines. 4 15 In parent application USSN 08/785,088 and concurrent publications it was shown that a recombinant adenovirus containing TK gene under the control of OC promoter, when supplemented with a prodrug ACV, could suppress osteosarcoma growth through intralesional injection in both rat and human osteosarcoma models. 1,4 Osteosarcoma, a bone cancer occurring primarily in teenagers and young adults, affects approximately 2100 individuals yearly in the United States (Boring, C.C., Squires, T.S., Tong, T., and Montgomery. S. Cancer statistics, 1994, CA Cancer J. Clin. , 44; 7- 26, 1994). This malignancy accounts for as many as 5% of all childhood malignancies and 60% of all malignant childhood bone tumors (Hudson, M., Jaffe, M.R., and Jaffe, N. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic actors derived from a 10 10-year experience. J. Clin. Oncol., 8: 1988-1997, 1990). Despite radical surgical resection of the primary tumor and aggressive adjuvant chemotherapy, the overall 2-year metastasis-free survival rate approaches only 66% . More than 30% of patients with this disease develop lung metastasis within the first year (Link, M.P., Goorin, A.M. , Mixer, A.W. , Link, M.P. , Goorin, A.M., Miser, A.W. , Green, A. A., Pratt, C.H. , Belasco, J.B. , Pritchard, J., Malpas, J.S., Baker, A.R. , Kirkpatrick, J.A. , Ayala, A.O. , Schuster, J.J. , Abelson, H.T., Simone, J.V., and Vietti, TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med, 314: 1600-1602, 1991. Goorin, A.M. , Perez-Atayde, A., Gebbhardt, M., et al. Weekly high- dose methotrexate and doxorubicin for osteosarcoma: the Dunn-Farber Cancer Institute/The Children's Hospital-Study III. J. Clin. Oncol., 5: 1178-1184, 1987). The survival rate among those affected with osteosarcoma has not changed significantly over the past 10 years, despite changes in adjuvant chemotherapy, Kane, M.J. Chemotherapy of advanced soft tissue and osteosarcoma. Semin. Oncol. , 16:297-304, 1989. The concept of delivery and expression of therapeutic toxic genes to tumor cells through the use of tissue-specific promoters has been well recognized. This approach could decrease the toxic effect of therapeutic genes on neighboring normal cells when virus- mediated gene delivery results in the infection of the normal cells. Examples include the uses of the albumin or oc-fetoprotein promoter to target hepatoma cells (Kuriyama, S., Yoshikawa, M. , Ishizaka, S., Taujli, T. , Ikenaka, K. , Kagawa, T., Morita, N., and Mikoshiba, K.A. potential approach for gene therapy targeting hepatoma using a liver- specific promoter on a retroviral vector, Cell Struct. Punct., 16: 503-510, 1991), the bone morphogenic protein promoter for brain to target glioma cells (Shimizu, K. Selective gene therapy of malignant glioma using brain-specific promoters; its efficacy and basic investigation, Nippon Rinsbo, 52: 3053-3058, 1994), the tyrosinase promoter to kill melanoma cells (Vile, R.G., Nelson, J.A., Castleden, S., Chong, H., and Hart, I.R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. , 54:6228-6234, 1994), and the carcinoembryonic antigen promoter for gastric carcinoma cells (Tariaka, T. , Kanai. F., Okabe, S. , Yoshida, Y. , Wakimoto, H., Hamada, H., Shiratori, Y. , Lan, K-H., Ishitobi, M., and Omata, M. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res., 46: 1341-1345, 1996). To date, the best studied therapeutic gene is herpes simplex virus TK gene. Herpes simplex virus-TK converts the pro-drug ACV to a phosphorylated form that is cytotoxic to dividing cells (Moolten, F.L., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes; paradigm for a prospective cancer control strategy. Cancer Res., 46:5276-5281, 1986). Critical to successful results is the "bystander" effect, which confers cytotoxicity on neighboring nontransduced cells; effective tumor cell kill can be achieved without the delivery to and expression of suicide genes in every tumor cell in vivo. This approach has been demonstrated recently to be efficacious in causing regression of many solid tumors, including metastatic colon carcinoma in the rat liver, (Chen, S.IL, Chen, X.H.L. , Wang, Y., Kosal, K.E. , Finegold, J.J. , Rich, S.S., and Woo, S.L.C., Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA. 92:2577-2581, 1995), gastric carcinoma, (Tanaka, T., Kanai. F., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H. , Shiratori, Y. , Lan, K-H. , Ishitobi, M. , and Omata, M. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen- producing human gastric carcinoma cells in vitro. Cancer Res. , 46: 1341-1345, 1996), and malignant mesothelioma (Smythe, W.R., Hwang, B.S., Elshami, A. A., Amin, K.M. , Eck, S., Davidson, B.L., Wilson, J.M., Kaiser, L.R., and Albelda, S.M. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. , 222:78-86, 1995). Osteocalcin (OC), a noncollagenous Gla protein produced specifically in osteoblasts, is synthesized, secreted, and deposited at the time of bone mineralization (Price, P. A. Vitamin-K dependent formation of bone GLA protein (onteocalcin) " and its function. Vitam. Horm., 42:65-108, 1985). A recent study showed that immunohistochemical staining of OC as positive in primary osteoblastic osteosarcoma and chondroblastic osteosarcoma specimens as well as in five of seven fibroblastic osteosarcomas (Park, Y.K. , Yung, M.H. , Kim, Y.W., and Park, H.R. Osteocalcin expression in primary bone tumors: in situ hybridization and immunohistochemical study. J. Korean Med. Sci., 10:268-273, 1995). In addition, OC activity was detected in a wide spectrum of human tumors. This is consistent with the clinical observations that many human tumors exhibited calcification characteristics both in the primary and at distant metastases. Because of the poor response rate of previously treated patients with relapsed osteosarcoma to second-line chemotherapy and the fact that many human solid tumors failed to respond to conventional chemotherapy and radiation therapy, it is important to develop new therapeutic approaches that can be applied either separately or in conjunction with current treatment modalities SUMMARY OF THE INVENTION The present invention relates to a novel therapeutic gene comprising a recombinant adenovirus (Ad), which contains an osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK), and which is represented by Ad-OC-TK, in a broad spectrum of human tumors that exhibit ability to calcify either in the primary or at metastatic sites. We noted that not only tumors but also non-tumor cells, as long as they have the ability to calcify, do express high OC-TK. Further, the present invention provides a method of treating a prototype of tumor, osteosarcoma, by intravenous, intratumoral or isolated regional perfusion of organs injection with the recombinant adenovirus, Ad-OC-TK. In addition, applicants have provided data to show that Ad-OC-TK eradicate the growth of localized prostate cancer and its osseous metastasis as well as the growth of brain tumor cells in vitro. The present invention also provides a method of treating osteosarcoma by the above routes of recombinant adenovirus Ad-OC-TK administration in combination with acyclovir (ACV). The Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro, murine osteosarcoma in vivo, human brain tumor cells in vitro, prostate carcinoma cell growth both in vitro and in vivo as localized and as osseous metastatic deposit. In addition the present invention provides a method for curing osseous metastatic tumors such as melanoma, breast cancer and prostate cancer, the treatment of tumors (e.g. osteosarcoma and prostate cancer) that metastasized to the lung, and the effect in inhibiting human brain tumor cell growth in vitro. The osteocalcin promoter, and therapeutic agent of this and the parent application, Ad-OC-TK, is not limited to the delivery of therapeutic genes for treatment of tumors. This system is also adapted for the treatment of normal tissue. Co-administration, systemically or locally, of Ad-OC-TK with acyclovir (ACV) may be effective in treating benign prostatic hypertrophy, as well as arteriosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein: Figure 1 depicts the construction of Ad-OC-TK, a recombinant adenovirus vector, containing the osteocalcin (OC) promoter driven toxic thymidine kinase (TK) gene. An expression clone PΔESP1-OC-TK and pJM17 was cotransfected into 293 cells, then recombinant Ad-OC-TK was generated and plaque purified. Figure 2 depicts determination of thymidine kinase (TK) activity in target cells infected with Ad-OC-TK. Cells were exposed to Ad-OC-TK (20 Mols per target cell), and their crude cellular lysate was obtained and assayed for TK activity. The mean TK activity was significantly higher in osteosarcoma ROS and MG-63 cells than in the WH and NIH 3T3 cell lines. Thymidine Kinase activity in ROS cells following infection with Ad-CMV- B-Gal was used as a negative control. Figure 3 depicts cytotoxicity of ACV in AD-OC-TK transduced osteoblastic ROS and MG-63 cells in vitro. The growth of murine osteogenic ROS (Figure 3, Panel A) and human osteosarcoma MG-63 (Figure 3, Panel B) cells, infected with 20 Mols of AD-OC- TK, was significantly inhibited by the addition of acyclovir (ACV) (10 μg/ml). Consistent with low levels of TK activity, the growth of WH (Figure 3, Panel C) and NIH 3T3 (Figure 3, Panel D) cells after AD-OC-TK infection was not affected by the addition of ACV in the tissue culture medium. Figure 4 depicts cytotoxicity of ACV in AD-OC-TK infected ROS tumor growth in vivo. ACV markedly suppressed the growth of ROS tumors following AD-OC-TK infection; AD-OC-TK infected ROS sarcomas or ACV treatment of tumor xenografts alone did not affect the rate of tumor growth. Figure 5 depicts cell-specificity of expression of AD-OC-TK. Androgen-dependent (LNCaP), androgen-independent (PC-3, C4-2, C4-2B, DU-145, and ARCAP) prostate cancer cell lines, glioma (U87), melanoma (1011) and breast (MCF-7B and NOA-MB-231) cancer cells expressed TK activity as assayed by the phosphorylation of [ 3 H]-GCV; low activity was detected in human bladder transitional cell carcinoma NM and a lung fibroblast cell line CCL-220. In other studies, it was shown that OC mRNA was expressed by a human lung cancer cell line. Figure 6 depicts effect of AD-OC-TK and acyclovir (ACV) in blocking PC-3 tumor growth in the skeleton. Mice were inoculated intra-osseously PC-3 tumor cells. 20 days after tumor cell inoculation, the animals were treated intra-osseously with AD-OC-TK and ACV. Note four treated animals had tumor regression in comparison to the four untreated animals which develop extensive osteolytic lesions and destruction of the bone. Figure 7 depicts wet lung weight in athymic mice treated with Ad-OC-TK, ACV, or combined Ad-OC-TK + ACV. Note: Ad-OC-TK and ACV combined treatment markedly decreased wet lung weight in athymic mice injected intravenously with ROS sarcoma cells. In this study, it was determined that lung weight correlated proportionately with tumor burden. Figure 8 depicts number of lung metastatic nodules in mice treated with ACV, Ad- OC-TK, or combined Ad-OC-TK + ACV. Note: Number of lung metastatic nodules were greatly decreased by combined treatment of Ad-OC-TK + ACV. Figures 9 to 16 show immunohistochemical staining of human tissues with osteocalcin antibody. Figure 9 shows that human bone tissues stained positively by osteocalcin antibody. Figure 10 shows that human colon cancer failed to stain by osteocalcin antibody. Figure 11 shows positive immunohistochemical staining of osteocalcin expression by human meningioma. Figure 12 shows positive immunohistochemical staining of lung bronchial alveolar carcinoma. Figure 13 shows positive immunohistochemical staining of papillary thyroid carcinoma. Figure 14 shows positive immunohistochemical staining of malignant mesothelioma. Figure 15 shows positive immunohistochemical staining of papillary ovarian carcinoma lung metastasis. Figure 16 shoes osteocalcin TK expression in various human brain tumor cell lines. Note: In comparison to rat osteosarcoma (assigned as 100%), an array of human brain tumor cell lines, including SK-N-SH (a human neuroblastoma cell line), A 172 (a human glioblastoma cell line), H4 (a human neuroglioma cell line), HS 683 (a human glioma cell line), CH-157MN (a human meningioma cell line), and HOG (a human oligodendroglioma cell line) all expressed high levels of osteocalcin TK activity; however, TLB-G (a normal human glial cell line), TC620 (a normal human oligodendrocyte cell line), WH (a human bladder transitional cell carcinoma cell line), and NIH 3T3 (a mouse fibroblast cell line) expressed low levels of osteocalcin TK activity. Fig.17 is a reproduction of H. and E. staining (Fig. lA) or immunohistostaining (IB, IC and ID) of lung tissue of nude mice receiving Ad-OC-B gal. The mice bore osteosarcoma lung metastases. Figure IB represents a control. Fig. 18 is a reproduction of stained tissue processed as described for Figure 1 25 days after tumor cell inoculation with the selected agent. Fig. 19 graphically depicts reduction in the number of metastatic nodules in treated mice. Fig. 20 graphically depicts the reduction in lung weight of treated animals. Fig. 21 is a photo reproduction of stained tissue samples showing a reduction in tumor nodule size in treated mice. Fig. 5 A reflects a control. Fig. 22is a graphic comparison of the survival rates of treated and non-treated mice. Fig. 23is a graphic comparison of body and prostate weight in normal intact rats, for both controls and treated rats. The abbreviations used throughout the specification and Figures are as follows: TK, thymidine kinase; OC, osteocalcin; Ad, adenovirus; ACV, acyclovir; FBS, fetal bovine serum; RSV, Rous sarcoma virus; β-tal, β-galactosidase; CMV, cytomegalo virus; GCV, ganciclovir; X-tal, 5-bromo-4-chloro-3-indolyl-β- galactopyranoxide; MOI, multiplicity of infection(s); ROS, rat osteoblastic osteosarcoma; MG 63, human osteosarcoma; SK-N-SH, human neuroblastoma; A 172, human glioblastoma; H4, human neuroglioma; HS 683, human glioma; TLB-G, human normal glia; CH-157MN, human meningioma; HOG, human oligodendroglioma; TC620, human normal oligodendrocyte; WH, human bladder cancer; 3T3 NIH, human fibroblasts. DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention provides for a therapeutic agent comprising a recombinant adenovirus (Ad) vector containing an osteocalcin (OC) promoter driven toxic thymidine kinase (TK) hereinafter represented by the formula: AD-OC-TK In another aspect of the present invention there is provided a method for treating a tumor comprising delivering a therapeutic agent to a tumor. The therapeutic agent comprises a recombinant adenovirus vector (Ad) containing an osteocalcin (OC) promoter driven toxic thymidine kinase (TK). In an additional aspect of the present invention a method for treatment of a tumor is provided which comprises delivering to the tumor a therapeutic agent containing a recombinant adenovirus (Ad) vector containing an osteocalcin (OC) promoter driven toxic thymidine kinase (TK) in combination with acyclovir (ACV). It is preferred that the therapeutic agent containing the Ad-OC-TK, in the presence or absence of ACV, be administered to osteosarcoma tumors, prostate and breast cancers, brain tumors, and their metastases to the lung, or osseous metastatic tumors such as melanoma, prostate or breast tumors. In another aspect of the present invention therapeutic application of Ad-OC-TK is provided to target cancers that metastasize to the lung and the skeleton. Whereas, osteosarcoma metastasize frequently to the lung, prostate cancer, breast cancer, and rare ocular melanomas metastasize prevalently to the bone and elicit either an osteoblastic or an osteolytic reaction. Applicants have unexpectedly discovered that Ad-OC-TK-infected osteosarcoma cell lines of the osteoblast cell lineage (e.g, ROS and MG-63 cells) expressed high levels of thymidine kinase (TK) activity while cell lines not of the osteoblast lineage, such as WH and NIH 3T3, expressed low TK activity. Further, Applicants have unexpectedly discovered that consistent with measured TK activity, the addition of acyclovir (ACV), a pro-drug substrate for TK, followed by Ad-OC-TK infection inhibited the growth of osteosarcoma cells lines in vitro and also sarcoma xenographs in vivo. The growth of WH and NIH 3T3 cells was not effected by Ad-OC-TK either with or without ACV administration. Thus, Applicants have unexpectedly discovered that Ad-OC-TK constitutes a tumor-specific toxic gene therapy that inhibits the growth of proliferating osteosarcoma cells and spares significant tissue damage in the surrounding non-proliferating normal tissues and cells that are of non-osteoblastic lineage. Further, the osteocalcin (OC) promoter-mediated gene delivery system is superior to conventional gene therapy in which TK expression is driven by universal promoters such as cytomegalovirus (CMV) promoter and the long terminal repeat promoters from Rous sarcoma virus (RSV) or moloney murine leukemia. Further, Ad-OC-TK, when delivered concurrently with ACV, is highly effective in inhibiting the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo. As mentioned above another potential therapeutic application of Ad-OC-TK is to target cancers that may metastasize to the lung and the skeleton. Although Applicants do not wish to bind themselves to any specific theories, they believe a possible mechanism for malignant cell recruitment to lung or bone is that osteosarcoma cells may have special affinity to deposit and grow in lung parenchyma and fibromuscular stromal network whereas osteogenic cells may synthesize and secrete products that are able to stimulate the growth, adhesion, and migration of the prostate or breast cancer cells. For the osteosarcoma patients, Ad-OC-TK is expected to have a direct cytotoxic effect on the growth of primary as well as metastatic osteosarcoma based upon data obtained from experimental models. The proliferation and migrating of prostate or breast tumor cells may secrete paracrine growth factors that stimulate osteoblast or osteoclast cell growth at sites of bone metastases that resulted in the induction of predominantly osteoblast (e.g., prostate cancer) or osteolytic (e.g., breast cancer) reactions in the skeleton. Since tumor cell growth is intimately affected by the surrounding stroma and reciprocal interactions exist between the growth of certain tumors (e.g., prostate and breast) and bone stroma, the development of a Ad-OC-TK is a new gene therapy modality for prostate or breast cancer patients. Thus, Ad-OC-TK therapeutic gene exhibits additional therapeutic implications: (a) Ad-OC-TK could block not only the growth of osteosarcoma but also eradicate osteoblastic cells that may be required to maintain the survival of osseous metastatic tumors such as prostate or breast tumors; although Ad-OC-TK may also eradicate the growth of normal osteoblasts, this appears not to be of concern because transgenic mouse bearing OC-TK treated with ACV did not affect their survival; (b) Ad-OC-TK could express high levels in a large number of calcified tumors and normal tissues. Thus, Ad-OC-TK plus ACV is a reasonable choice for eradicating the group of a primary tumor and its metastasis and normal calcified tissues such as atherosclerotic plagues; (c) Ad-OC-TK may be used in conjunction with conventional chemotherapy and radiation therapy in reducing tumor burden and pain associated with local tumor growth as well as osseous metastases; and (d) long-lasting anti-tumor immunity might be elicited against the remaining osteoblastic cells from TK- induced killing of tumor cells. In addition, Ad-OC-TK was injected into syngeneic or athymic mice bearing osteosarcoma metastases in the lung and have observed marked reduction of tumor burden in the lung as evaluated by the wet weight of the lung. Prostate cancer metastasizes primarily to the skeleton. Applicants have demonstrated that osteocalcin (OC) promoter drives the expression of therapeutic toxin gene Herpes Simplex Virus (HSV), thymidine kinase (TK), in osteoblast and non-osteoblast cell types, including androgen-dependent and androgen- independent prostate cancer cells. Applicants have shown that Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of human prostate cancer in vitro and in vivo. Relevant documents reflecting the inventors' own work, and not prior art, include Ko et al, Human Gene Therapy, 7: 1683-1691 (Sept. 1996) and Ko et al. , Cancer Research 56, 4614-4619 (October, 1996). Applicants have further developed an OC promoter-based suicide gene therapy, driven by vitamin D 3 analogs, to kill both androgen-dependent and androgen independent prostate cancer cells and their supporting stroma. Although Applicants do not want to bind themselves to any theory they believe that Vitamin D 3 analogs appear to have dual action in promoting prostate cancer differentiation (inhibiting prostate cancer proliferation) and drive the expression of therapeutic toxic genes in both cancer epithelium and bones stroma. Thus, a novel therapeutic agent comprising a recombinant Ad-OC-TK virus was generated. Further, a method is provided where the novel therapeutic agent Ad-OC-TK can selectively target and induce the killing of osteoblast lineage cells and a wide spectrum of tumor cells that have the ability to calcify either at the primary or at distant metastases. Further, a new recombinant Ad-OC-TK therapy agent is provided for osteosarcoma patients as well as for patients with melanoma, brain tumors, tumors metastasized to the lung and osseous metastatic tumors such as melanoma, breast cancer, or prostate cancer. Other toxins may be substituted for TK. Genes for cytosine deaminase, p53 tumor suppressor gene, and cyclic regulatory proteins, including various cytokines, and others, e.g. , pl6, p21 can be used in this invention in place of TK genes. Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purpose of illustration only and are not intended to be limiting unless otherwise specified. In the development of this invention, three distinct phases or areas of development are identifiable. First, the invention involves development of the active agent and its direct administration to tumors. Second, the invention had been demonstrated to be surprisingly effective against metastatic cancers when administered intravascularly, including intravenously. Third, the invention has been demonstrated effective in the treatment of benign conditions such as benign prostatic hypertrophy (BPH) and arteriosclerosis. These three developments are discussed below, in sequence. Development of the Effective Agent and Direct Administration EXAMPLES Cells and Cell Culture. ROS 17/2.8, a rat osteoblastic osteosarcoma cell line, which is obtained by harvesting cells from tumor explants grown in culture (ROS 17/2.8 was obtained from the University of Texas Dental Branch, Houston, TX). MG-63, a human osteoblast-derived osteosarcoma cell line; 293, a transformed human embryonic kidney cell line; and NIH 3T3, an embryonic mouse fibroblast cell line, were purchased from American Type Culture Collection (Rockville, MD). WH, a human bladder transitional cell carcinoma, was established by our laboratory (described in Gleave, M.E., Haich, J.T., Wu, H.C., Hong, S.J. Zhau, H.E., Guthrie, P.D., and Chung, L.W.K. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res., 53: 5300-5307, 1993). The ROS 17/2.8 and MG-63 cell lines are considered the osteoblast lineage because of their morphological, biochemical, and molecular characteristics, they were incubated in DMEM (Life Technologies, Inc., Grand Island, NY) and 20% F12K (Irving Scientific, Santa Ana, CA) supplemented with 100 units/ml penicillin, 100 μ/ml streptomycin, and 10% FB5 (Sigma Chemical Co., St. Louis, MO). The WH and NIH 3T3 cell lines were maintained in T medium, (as described in Ko, S-C, Gotoh, A., Thalmann, G.N. , Zhou, H.E. , Johnston, D.A., Zhang, W.W., Kao, C, and Chung, L.W.K. Molecular therapy with recombinant p53 adenovirus in an androgen independent, metastatic human prostate cancer model. Hum. Gene Ther., 7: 1683-1691, 1996), containing 5 % FBS (fetal bovine serum). The 293 cells were maintained in MEM (Life Technologies, Inc.) with 10% FBS and 1 % tryptose phosphate broth (Life Technologies, Inc.). The cells were fed three times a week with fresh growth medium unless otherwise indicated. Construction and Large-scale Production of a Recombinant Ad Vector Containing the OC Promoter-TK. Construction of the recombinant Ad-OC-TK virus was accomplished as shown in Fig. 1. All plasmids were constructed according to standard protocols. Briefly, pΔElSPl, a shuttle vector which contains the 5' end part of the adenovirus genome with El -region deleted, was digested with Xho-1 (New England Biolabs, Beverly, MA) and treated with alkaline phosphatase (Boehringer Mannheim Biochemicals, Indianapolis, IN) according to the supplier's protocols. The Xho-1 -digested 3.1-kb fragment containing the murine OC promoter (1.3 kb)-driven TK (1.8 kb) construct was generated from pill .5 plasmid and ligated into pΔElSPl Ad vector using T4 ligase (New England Biolabs). The recombinant shuttle vector, p2ΔElSPl-OC-TK, is co- transfected with pJM17, a circular adenovirus genome (with El region deleted and replaced with PBR322 DNA) purified from adenovirus infected cells, into 293 cells by the N-[l- (2,3-dioleoyloxyl)propyl]-N,N,N-trimethylammoniummethyl sulfate (Boehringer Mannheim Biochemicals)-mediated transfection method, Zhang, W-W., Fang, X. , Branch, CD. , Mazur, W., French, B.A., and Roth, J.A. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis, Biotechniques, 15:868- 872, 1993. The culture medium of the 293 cells showing the completed cytopathic effect was collected and centrifuged at 1000 x g for 10 minutes. The pooled supernatants were aliquoted and stored at -80°C as primary viral stock. Viral stocks were propagated in 293 cells, and selected clones of Ad-OC-TK virus were obtained by plaque purification according to the method of Graham and Prevec, Graham, F.L., and Prevec, L. Manipulation of adenovirus vectors, Vol. 7, pp.109-128. Clifton, NJ: The Humana Press, Inc., 1991. One of the viral clones was propagated in 293 cells; cells were harvested 36 to 40 hours after infection, pelleted, resuspended in PBS, and lysed. Cell debris was removed by subjecting the cells to centrifugation, and the virus in the cell lysate was purified by CsCl 2 gradient centrifugation. Concentrated virus was dialyzed, aliquoted, and stored at - 80 °C. The viral titer was determined by plaque assay. The control viruses used in this study, Ad-RSV-β-Gal and Ad-CMV-β-Gal, were constructed in a similar manner (described in Ko, S-C , Gotoh, A., Thalmann, G.N., Zhou, H.E., Johnston, D.A. , Zhang, W.W. , Kao, C, and Chung, L.W.K. Molecular therapy with recombinant p53 adenovirus in an androgen independent, metastatic human prostate cancer model. Hum. Gene Ther. , 7: 1683-1691, 1996). X-Gal Staining of Ad-RSV-β-Gal Virus-Infected Cells. ROS, MG-63, WH, and NIH 3T3 cells, after infected with various doses of recombinant Ad-RSV-β-Gal, were grown in 60-mm dishes to about 80-90% confluency for 2 days, then the medium was discarded and fixed with 0.05 % glutaraldehyde. After discarding the fixative solution, cells were rinsed thoroughly three times in PBS at room temperature. An X-Gal solution mixture [0.5 ml; 35 mM K 3 Fe(CN) 6 ; 35 mM K 4 Fe(cCN) 6 3H 2 O, 1 mM MgSO 4 , and 1 mg/ml X-Gal (Sigma Chemical Co.)] was added to cover cells. Cells were then incubated 1 hour to overnight at 37°C. Positive cells were stained blue, and the percentage of blue cells was calculated. Determination of TK Activity In Target Cells Infected with Ad-OC-TK. Crude cell extracts containing TK were prepared from Ad-OC-TK-infected ROS, MG-63, WH, and NIH 3T3 cells. Briefly, cells were cultured in 100-mm dishes in 60 to 70% confluency, at which point they were exposed to 20 MOI (multiplicity of infections) of Ad- OC-TK overnight. The culture medium was then replaced with fresh medium after overnight infection, and the replaced culture medium was removed after an additional 48 hours incubation. The infected cells were washed with PBS, trypsinized, and then counted; the expressed TK enzymatic activity was recovered from cells by the repeated freeze and thaw method. The resultant cell suspension was centrifuged at 300 x g for 10 minutes, and the supernatant fraction was frozen at -80 °C for TK activity assay. TK activity was assayed by phosphorylation of [ 3 H]GCV, as described previously, Graham and Prevec, Graham, F.L. , and Prevec, L. Manipulation of adenovirus vectors, Vol. 7, pp.109-128. Clifton, NJ: The Humana Press, Inc., 1991, with modification. Briefly, the supernatant fraction harvested from approximately 1 x 10 6 cells containing TK was mixed with an equal volume of TK assay buffer containing 0.2 μCl of [ 3 H]GCV (10 μm; Moravek Biochemicals, Brea, CA), 3 mM MgCl 2 , 3mM ATP (adenosine triphosphate), 10 μglμl BSA (bovine serum albumin), and 50 mM sodium phosphate buffer (pH 6.5). The reaction mixture was incubated in a 36 °C water bath for 90 minutes and the reaction mixture was transferred onto DE-81 discs (Whatman, Hillsboro, OR), air-dried, and washed thoroughly with 50% ethanol. Phosphorylated [ 3 H]GCV bound to the filter discs was determined with a scintillation counter (Beckman Instruments, Inc., Schaumburg, IL). GCV, a substrate for TK, differs from ACV (Burroughs Wellcome, Research Triangle, NC) structurally only by the addition of a hydroxymethyl group. Because of this one side chain difference, GCV is administered only through an i.v. route, whereas ACV can be administered p.o. , i.v. , and topically to humans, ACV and GCV are both commonly used clinically against heφes virus infection. In this communication, because of the availability and rate of absorbency, [ 3 H]GCV is used to assay TK activity assay, whereas ACV is used for both the in vitro and in vivo studies. Acyclovir in Vitro Cytotoxicity Assay. To determine ACV dose-response curves, ROS, MG-63, WH, and NIH 3T3 cells were plated in 24-well Falcon tissue culture plates (Falcon Products, Franklin Lakes, NJ) and exposed to various concentrations of ACV ranging from 10 to 1000 μg/ml media. Cell numbers were measured daily by the crystal violet assay using an automated Emax spectrophotometric plate reader (Molecular Devices Coφ., Sunnyvale, CA). Ad-OC-Tk plus ACV-induced in Vitro Cytotoxicity Assay. ROS, MG-63, WH, and NIH 3T3 cells were seeded onto 24-well plates at a density of 5.0 x 10 3 cells/well. After 24 h, the cells were infected with FBS (fetal bovine serum), or Ad-OC-TK at a concentration of 20 MOI (multiplicity of infection) for 8 h. Following infection the medium containing Ad-OC-TK was replaced with fresh medium containing 0 or 10 μg/ml ACV with daily medium changes for an accumulated period of 7-9 days. The cell number per well was assessed by crystal violet assay as described above. Ad-OC-TK and ACV-induced Inhibition of Tumor Growth in Vivo. Congenitally athymic nude (nu/nu) mice (Harlan Co., Houston, TX) 5 to 6 weeks of age, were inoculated s.c. with ROS (3 x 10°)cells, a rat osteosarcoma cell line. When the tumor became palpable (4-5 mm in diameter), the animals were randomly assigned to three experimental groups: group 1, ACV only; group 2, Ad-OC-TK only; and group 3, Ad- OC-TK plus ACV. For Ad-OC-TK injection, a microliter syringe fitted with a 28-gauge needle was used to deliver 75μl of Ad-OC-Tk (1 x 10 9 plaque-forming units). The Ad-OC- TK was injected intratumoraHy along both the long and short axes of the tumor; one injection parallel to the long axis, and one peφendicular to the axis. The needle point was then rotated within the tumor to maximize the area of Ad delivery, Ad-OC-TK was injected every other day for a total of three doses. Tumor volume was calculated by the following formula: volume (a rotational ellipsoid) = M x x M 2 2 x 0.5236 ( ,, long axis; M > , short axis; Ko. S-C , Gotoh, A. , Thalmann, G.N., Zhou, H.E., Johnston, D.A., Zhang, W.W. , Kao, C, and Chung, L.W.K. Molecular therapy with recombinant p53 adenovirus in an androgen independent, metastatic human prostate cancer model. Hum. Gene Ther., 7: 1683-1691, 1996). Acyclovir (ACV) treatment only or Ad-OC-TK plus ACV experimental groups were treated with an i.p. injection of ACV at a dose of 40 mg/kg body weight daily for 7 days. Ad-OC-Tk and/or ACV treatment did not adversely affect the body weight of experimental animals. Tumor volume was calculated every other day for the first 8 days on day 20 and day 32. Adenoviral Transduction Efficiently to ROS and MG-63 Cells and TK Expression in Vitro. To test the efficiency of Ad infection in ROS, ' a rat osteogenic sarcoma cell line, and in Mg-63, a human osteosarcoma cell line, we used a recombinant adenoviral vector containing the RSV-β-Gal expression cassette (Ad-RSV-β-Gal). Based upon X-Gal staining of β-Gal activity, a dose-dependent increase of Ad infection was noted in ROS and MG-63 cells, with the percentage of cells infected gradually 6, 75, and 100% as the adenoviral MOI increased 20, 40, and 60 MOI per target cell. A similar efficiency of adenoviral infection was observed in WH and NIH 3T3 cells. In comparison to uninfected control cells, mild cytotoxicity was noted through the application of Ad up to 60 MOI. To assess whether Ad-OC-TK may drive the expression of the TK gene in a cell type-specific manner, ROS, MG-63, WH, and NIH 3T3 cells were exposed to Ad-OC-TK (20 MOI/target cell), and their crude cellular lysates were obtained and assayed for TK activity. TK activity was indirectly determined by measuring the amount of phosphorylated [ 3 H]GCV phosphorylation (i.e., TK activity) per 10 6 cells was significantly higher in osteosarcoma ROS and MG-63 cells than in the WH and NIH 3T3 cell lines (Fig. 2). TK activity in ROS cells following infection with 20 MOI of Ad-CMV-β-Gal, Ko. S-C, Gotoh, A. , Thalmann, G.N. , Zhou, H.E., Johnston, D.A. , Zhang, W.W. , Kao, C , and Chung, L.W.K. Molecular therapy with recombinant p53 adenovirus in an androgen independent, metastatic human prostate cancer model. Hum. Gene Ther., 7: 1683-1691 , 1996 serves as a negative control. Cytotoxicity of ACV in Ad-OC-TK-transduced ROS and MG-63 Cells in Vitro. To determine whether Ad-mediated transduction with the OC-TK gene would render ROS or MG-63 cells sensitive to cell killing by ACV, we first tested the toxicity of ACV (range, 0-1000 g/ml) in non-infected ROS, MG-63, WH, and NIH 3T3 cells and observed that ACV at doses below 40 μg/ml did not appreciably inhibit the growth of all cell lines tested (data not shown). The growth of ROS (Fig. 3 A) and MG-63 (Fig. 3B) cells, infected with 20 MOI of AD-OC-TK, was significantly inhibited by the addition of ACV (10 μg/ml); cells infected with Ad-OC-TK (20 MOI/target cell) or treated with ACV (10 g/ml) alone did not exhibit altered growth or moφhology during a 7-9 day observation period. Consistent with the low levels of TK activity, the growth of WH (Fig. 3C) and NIH 3T3 (Fig. 3D) cells after Ad-OC-TK infection was not affected by the addition of pro-drug ACV in the cell culture medium. Similarly, Ad-OC-TK or ACV alone did not affect proliferation in these cells. Cytotoxicity of ACV in Ad-OC-TK-infected ROS Tumor Growth in Vivo. ROS sarcoma xenografts were induced by s.c. injection of ROS cells (1 x 10 6 cells/site) in athymic mice. After tumor formation, animals were treated with either ACV alone, Ad- OC-TK alone, or Ad-OC-TK plus daily ACV i.p. injection. After completion of a 7-day course of ACV, the Ad-OC-TK plus ACV treated group demonstrated no ROS tumor growth for up to 8 days and a significantly decreased growth rate for up to 20 days. (Fig. 4). After 1 month, the normal growth rate of ROS tumor resumed, and the experiment was terminated, Ad-OC-TK infection or ACV treatment alone did not affect the rate of tumor growth. Development of Therapeutic Toxic Gene Therapy in Experimental Models of Human Prostate Cancer Bone Metastasis: Osteocalcin Promoted-based Toxic Gene Therapy. Ad-OC-TK adenoviral vector was constructed as described above and the replication defective viruses were produced. A monolayer of a number of human cell lines were exposed to Ad-OC-TK, and TK activity and acyclovir-induced cell-kill were determined Ad-OC-TK anti-tumor activity was also tested in vivo by intratumor injection (subcutaneously) or intraosseous injection to previously established prostate tumors grown in the long bone. Therapeutic responses to tumors were determined by tumor size, histomoφhology, apoptosis, and/or serum PSA (for LNCaP sublines C4-2 and C4-2 B induced tumors). Ad-OC-TK expressed in both osteoblast-lineage cell types (ROS, MG63, MS), androgen-sensitive (LNCaP), and androgen-insensitive (C4-2, C4-2 B, DU-145, and PC-3) human cancer epithelial cell lines. Ad-OC-TK infection followed by acyclovir supplementation effectively eliminated the growth of osteoblast and non-osteoblast lineage tumor cell growth both in vitro and in vivo subcutaneously. Moreover, the growth of prostate tumors at the bone marrow space was notably eliminated, based upon histomoφhologic X-ray and bone scan observation, at the end of a 30 day treatment period. Vitamin D 3 -Enhanced Osteocalcin Promoter-based Suicide Gene Therapy. An adenoviral vector (Ad-OC-TK) consisting of OC promoter-suicide gene, thymidine kinase (TK), was constructed. This vector was found to be highly infectious against an array of prostate cancer and bone stromal cell lines. To enhance OC promoter activity, vitamin D 3 and its analogs were tested. Ad-OC-TK activity was found to be expressed by a variety of human cancer cell lines, including osteosarcoma, prostate, melanoma, and breast; Ad-OC-TK, however, was not expressed by a human bladder transitional cell carcinoma cell line, WH, and NIH-3T3 cells. Intracellular TK activity was found to correlate well with acyclovir-induced cell-kill both in vitro and in vivo. Systemic Administration and the Treatment of Metastatic Cancer In the foregoing portion of this application, we have demonstrated, in vitro and in vivo, the effectiveness of direct administration of Ad-OC-TK in the treatment of tumors. This agent is also effective in systemic delivery. In this portion of the application, we demonstrate the efficacy of the treatment of osteosarcoma pulmonary metastases with a systemic delivery route of Ad-OC-TK supplemented with ACV. We established osteosarcoma lung metastases in nude mice by intravenous injection of rat osteosarcoma cells, ROS 17/2.8. ROS 17/2.8 cells colonized and formed tumor nodules within one week in the lungs of nude mice. Whereas systemic delivery of Ad- RSV-β Gal(recombinant adenoviral vector containing E. coli beta-galactosidase gene driven by a rous sarcoma virus universal promoter) resulted in non-specific expression of beta- glactosidase (β-gal) activity in the lung parenchyma, Ad-OC-β Gal administration resulted in specific β-gal expression in tumor cells deposited in the lung. When nude mice bearing ROS 17/2.8 lung tumors were treated with systemic Ad-OC-TK through tail vein administration, subsequent intra peritoneal ACV treatment significantly decreased the number of tumor nodules (p < 0.0001) and the net lung wet weight (p =0.0005), and increased significantly (0.005 <p < 0.01) the survival of animals when compared to untreated and Ad-OC-TK or ACV-treated control groups. These results suggest that Ad- OC-TK plus ACV may be used as a systemic therapy for the treatment of osteosarcoma lung metastasis. MATERIALS AND METHODS Cells and Cell Culture ROS 17/2.8, a rat osteoblastic osteosarcoma cell line, was generously provided by Dr. Cindy Farrach-Carson (The University of Texas Dental Branch; Houston, Texas). ROS 17/2.8 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO BRL, Grand Island, New York) supplemented with penicillin (100 units/ml), streptomycin (100 mg/ml), and 10% fetal bovine serum (FBS) (Sigma Chemical Co., St. Louis, Missouri). The cells were fed three times a week with fresh growth media. Construction and Preparation of Recombinant Adenoviral (Ad) Vectors The construction of recombinant Ad vector containing OC promoter-TK (Ad-OC- TK) was described previously. 4 The recombinant OC promoter-β glactosidase (Ad-OC-β gal) or RSV (Rous Sarcoma virus) promoter-β glactosidase (Ad-RSV-β gal) was constructed similarly to Ad-OC-TK using the same protocol. Briefly, OC or RSV promoter plus E. coli β glactosidase (lacZ) gene and the polyadenylation signal from simian virus 40 were cloned first into a plasmid pΔElsplA (a gift from Dr. Frank Graham, McMaster University, Hamilton, Ontario, Canada), to generate the shuttle vectors, pΔElsplA-OC-β gal or pΔElsplA-RSV-β gal, respectively. The replication-defective adenovirus, Ad-OC-β gal and Ad-RSV-β gal were produced by cotransfecting pΔElsplA-OC- β gal or pΔElsplA-RSV-β gal with a recombinant adenoviral vector pJM17 into 293 cells using a DOTAP (Boehringer Mannheim Biochemicals) mediated transfection method. 16 The cell lysates were prepared from dishes that showed the cytopathic effect of adenovirus infection. A PCR analysis was conducted to identify the recombinant as well as the wild- type adenoviruses. 16 Recombinant adenoviruses were propagated in 293 cells and purified by the CsCl centrifugation method. 17 the purified virus stock was then dialyzed against 10 mM Tris buffer pH 7.5 containing 1 mM MgClj and 10% glycerol. The plaque-forming unit (PFU) of the viruses was measured by a standard biologic plaque forming assay and OD measurements. 17 Animal Model of Osteosarcoma Pulmonary Metastasis Athymic Balb/c (nu/nu) mice at 5 to 6 weeks were purchased from Harlan Co. (Houston, Texas). Tail vein injection of 5 X 10 5 ROS 17/2.8 cells in 50 μl of culture medium resulted in 100% histological incidence of pulmonary metastasis at 7 days (n-8, data not shown). All mice were maintained in facilities approved by the American Association of Accreditation of Laboratory Animal Care, and all animal studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals. Immunohistochemical Staining The removed lung tissues were fixed in 4% buffered formaldehyde, embedded in a paraffin block, and then sectioned. Tissue sections were deparaffinized, treated with 3% hydrogen peroxide (H 2 O 2 ) and blocked with Super Block (Scytek Laboratories, Logan, Utah). To detect the expression of bacterial β-glactosidase, tissue sections previously blocked with Super Block were incubated with either 1:1000 diluted rabbit anti-E. Coli β gal polyclonal antibodies (5 prime-3 prime, Inc., Boulder, Colorado) or control rabbit serum at 4°C for 24 hrs. Tissue sections were washed thoroughly and incubated for 1 hour with biotinylated goat anti-immunoglobulin antibody (Multilink) followed by 1 hour incubation with peroxidase-conjugated streptavidin (Label, BioGenex Laboratories, San Ramo, California) at room temperature. Finally, the tissue sections were incubated with the substrate 3-amino-9-ethylcarbazole (AEC) for color development. Treatment of Pulmonary Metastasis by Ad-OC-TK The osteosarcoma pulmonary metastasis model was established as described above. Ad-OC-TK (5 X 10 8 PFU per 50μl) was injected via tail vein twice, at day 7 and 14, after ROS 17/2.8 injection. Daily acyclovir intra peritoneal administration (40 mg/kg body weight) started at day 6 after ROS 17/2.8 tumor cell inoculation and continued for 15 days. All animals were sacrificed and examined on day 25. The lungs were removed, photographed, and weighed, and the metastatic deposits were observed under a low- powered (20X) stereo microscope. Histomoφhologic observations were made in all specimens according to a standard procedure. Student's t-test was employed to analyze the statistical significance of differences among control and treatment groups. Long Term Survival Study The end-points of the long term survival study are: animal death or sacrifice upon request by animal care takers because of excessive tumor burden causing animal distress, lethargy, ruffled fur or weight loss. The survival rate of the animals was analyzed by the Kaplan-Meier survival curve. The statistical significance of this study was analyzed with the generalized Wilcoxon test. 18 RESULTS Establishment of Osteosarcoma Lung Metastasis The ability of ROS 17/2.8 cells to colonize and form tumors- in the lungs of nude mice was tested by injection of cells directly into the tail vein. Two inoculating cell numbers, 5 X 10 5 and 1 X 10 6 cells, were selected for intravenous administration via tail vein to mice. Tumor nodules were found in the lungs of all animals within one week (4 animals per group). Lung metastases appeared to be specific because on complete necropsy no other organs were found to harbor gross tumor mass. An additional forty-six animals studied subsequently demonstrated pulmonary metastasis on exploration at various time points beyond one week. Specific Targeting of Osteosarcoma Lung Metastasis with Intravenous Osteocalcin Promoter-Driven Gene Therapy In order to test whether the OC promoter can mediate gene expression in normal lung cells, we constructed Ad-OC-β gal and Ad-RSV-β gal with transcriptional control of the β gal gene expression under the OC promoter and the universal promoter from Rous Sarcoma virus (RSV), respectively. Ad-OC-β gal (1 X 10? PFU in 50μl), Ad-RSV-β gal (1 X 10 9 PFU in 50μl of phosphate buffered saline (PBS) as a control was injected via tail vein of mice 7 days after ROS 17/2.8 cells injection. Mice were sacrificed and the lungs were removed for further analysis 48 hours after a single tail vein injection. The expression of β gal in the lung tissue and tumor nodules was detected by immunohistochemical staining with anti-bacterial β gal antibody. In the Ad-RSV-β gal treated mice, the anti-β gal immunoreactivity was observed in both osteosarcoma lung metastases and normal lung tissue (Figure 17 c). Conversely, in the Ad-OC-β gal treated mice, the anti-β gal immunoreactivity was detected primarily in osteosarcoma lung metastases and not in normal lung tissue (Figure 17 d). No anti-β gal immunoreactivity was observed in the PBS treated host (Figure 17 b). These results demonstrate that OC promoter-mediated gene expression is localized preferentially in osteosarcoma tumors deposited in the lung but not in normal lung tissues. Suppression of Osteosarcoma Lung Metastasis with Intravenous Ad-OC-TK Gene Therapy We next tested the therapeutic efficacy of intravenous Ad-OC-TK gene therapy for the treatment of osteosarcoma lung metastases. Twenty mice bearing ROS 17/2.8 tumor lung metastases were treated with either PBS (control), Ad-OC-TK alone, ACV alone, or Ad-OC-TK plus ACV. Animals were sacrificed and analyzed on day 25 after ROS 17/2.8 inoculation. Tumor nodules on the lung surface were counted with stereo-optic magnification and the lung wet weights were measured, and all the lung specimens were subjected to histological analysis. Grossly, metastatic lung nodules were observed on the lung surfaces in all of the animals (figure 18 a-d). In the Ad-OC-TK plus ACV treated group, both the number of nodules (p < 0.0001) and the lung wet weight (p= 0.0005) were significantly lower than in the PBS-treated control group (figure 19, 20). Histologically, osteosarcoma pulmonary metastases were identified in the lung tissue of all twenty animals. No statistical difference was demonstrated in either the number or the size of pulmonary metastases in the PBS, Ad- OC-TK alone, or ACV alone control groups. In comparison to PBS-treated specimens (figure 21 a), the tumors in animals treated with Ad-OC-TK and ACV had a marked decrease in tumor size and demonstrated extensive necrosis (See Figure 21 b arrows). Prolonged Survival with Ad-OC-TK Gene Therapy Twenty-six mice were inoculated with ROS 17/2.8 tumor cells as described above. Animals received either PBS, Ad-OC-TK alone, ACV alone, or Ad-OC-TK plus ACV and survivals were compared. No obvious difference in survival was detected among 3 control groups: PBS, Ad-OC-TK alone, or ACV alone. The survival of Ad-OC-TK plus ACV treated group, however, was significantly (0.005 <p < 0.01, generalized Wilcoxon test) prolonged. Mean survival time was 27.1 ±2.9 days for the control animals and 36.6+5.8 days for the Ad-OC-TK plus ACV-treated animals (figure 22). DISCUSSION Since lung epithelium contains the first capillary bed encountered by therapeutic agents given systemically, several investigators have explored the use of a venous system to deliver therapeutic genes to the lung by cationic liposomes 7 ' 19"21 or retroviral vectors. 8 This application describes a new treatment strategy to target pulmonary metastases using a tumor-specific osteocalcin promoter-based toxic gene therapy given via a systemic route. We have shown recently that intratumoral injection of Ad-OC-TK to both human and rat osteosarcoma tumors grown at subcutaneous sites, significantly impaired tumor growth in vitro and in vivo. Moreover, we noted that combined administration of Ad-OC-TK/ ACV plus methotrexate improved further the therapeutic efficacy of gene therapy for osteosarcoma cell growth both in vitro and in vivo. These results are set forth in parent U.S. Patent Application Serial No. 08/785,088. Since osteosarcoma metastasises primarily to the lung, and lung vasculature is considered as the first major capillary bed that a systemically-given therapeutic agent encounters, we designed a strategy to target osteosarcoma pulmonary metastasis by the administration of Ad-OC-TK/ ACV in an animal model, β-glactosidase reporter gene expression under the transcriptional control of the osteocalcin promoter is specifically expressed in osteosarcoma cells rather than normal lung parenchyma. In comparison to control animals, systemically delivered Ad-OC-TK plus ACV (via intravenous route) significantly retarded the growth of osteosarcoma pulmonary metastases and improved survival of treated animals. While a limited number of tumor cells in the lung may be infected by Ad-OC-TK, as judged by the immunostaining of a comparable virus, Ad-OC-β gal (figure Id), a suφrisingly potent growth-inhibiting effect by Ad-OC-TK/ ACV was noted in osteosarcoma lung metastases. This biologic effect is most likely derived from the existence of close gap junctions between osteosarcoma cells 22 which allows the phosphorylated form of ACV to exert its full bystander effect. The observation that Ad-OC-TK/ ACV delivered by an intravascular route effectively inhibited the growth of osteosarcoma lung metastases raises the question of delivering therapeutic viruses via local regional perfusion. For example, employing a Swan-Ganz type catheter may achieve improved local delivery. Isolated single-lung- perfusion technique for the chemotherapy of lung metastasis has increased the concentration of chemother apeutic agents in human lung by 10-20 fold. 23 This technique offers promise for the delivery of Ad-OC-TK and subsequent treatment of osteosarcoma lung metastasis through systemic administration of ACV. The loco-regional delivery of gene therapy can achieve higher local viral concentration and infectivity, and reduce viral leakage systemically. It is also expected that this route of gene therapy delivery will avoid the interference of neutralizing antibody which can be flushed out of lung circulation prior to adenovirus administration. We are currently developing this loco-regional technique for the treatment of osteosarcoma pulmonary metastasis using a larger size of animal model (e.g. nude rate) in our laboratory. In summary, we have shown for the first time that recombinant adenovirus can be given systemically to achieve a therapeutic effect on osteosarcoma lung metastasis. Ad-OC- TK/ ACV dramatically inhibited the growth of lung nodules and significantly increased the survival of animals bearing osteosarcoma pulmonary metastases. This approach will open new avenues for targeting pulmonary metastasis using tissue-specific or tumor-specific promoters to guide the expression of therapeutic genes. Systemic Treatment of Benign Conditions The therapeutic agent that is the subject of this application, Ad-OC-TK is not limited in its uses to the treatment of cancer. A variety of benign conditions can also be addressed by the systemic administration of Ad-OC-TK, alone, or in combination with acyclovir (ACV). These conditions include benign prostatic hypertrophy and arteriosclerosis. Benign prostatic hypertrophy (BPH) is a nearly universally observed symptom of aging in mammalian males, including humans. The enhanced growth of the prostate gland observed in this syndrome can be controlled by administration of Ad-OC-TK. Following the protocols set forth above normal male rats were collected and received therapeutically effective amount of Ad-OC-TK and ACV. Controls received placebo, or ACV alone. The rats receiving the treatment, Ad-OC-TK 5 x 10 s PFU (50 ul of 1 x 10 10 PFU/ml stock) and ACV (14 days intraperatenial injection)showed a positive response in terms of inhibition of growth of the prostate gland. All animals were sacrificed after one month of treatment and began the program with an average body weight of 300 grams. Importantly, while prostate growth was inhibited, body weight values did not differ significantly. Fig. 23. Clearly, administration of Ad-OC-TK in any sort of pharmaceutically effective carrier, particularly administered systemically, i.e. , intravascularly, is effective in treating mammalian, including human, BPH. This is confirmed by findings which demonstrate that Ad-OC-β-glactosidase and Ad-CMV-β-glactosidase are principally expressed in cultured primary human prostate cells derived from a BPH specimen, confirming effective delivery of this gene therapy region. Arteriosclerosis is accompanied by the formation of arteriosclerotic plaques surrounding effective blood vessels. Osteocalcin expression is increased in these plaques. Frequently, the over expression of OC in these tissues is associated with increased calcium deposition. Jie et al., Calcified Tissue Intl. 59:352-356 (1996) and Jie et al., Atherosclerosis 116:117-123 (1995). See also Balica et al., Circulation 95: 1954-1960 (1997). The over expression of OC, and accompanying calcium deposition, around the arteriosclerotic plaques formed lends itself to Ad-OC-TK-mediated gene therapy. The combined administration of this therapeutic agent, optionally coupled with the administration of ACV, offers gene therapy for actual regression of arteriosclerotic plaque, and effective treatment of arteriosclerosis. A more detailed understanding of Figures 17-22 may be had by reference to the following figure legends. Figure 17. Tissue specific targeting of osteosarcoma lung metastasis with Ad-OC-β gal. PBS (50μl), Ad-OC-β gal (1 X 10? PFU per 50μl) or Ad-RSV-β gal ( 1 X 10? PFU per 50μl) was injected via the tail vein of a nude mice bearing osteosarcoma lung metastases to study tissue specific activity of OC promoter in lung environment. Animals were sacrificed two days after virus inoculation. Lungs were removed and processed for H. and E. staining (a) or immunohistostaining with anti-β gal antibody (b, c and d). H. and E. staining showed the presence of osteosarcoma lung metastasis (a). Control animals received PBS alone and did not show brown positive stain with anti-β gal antibody (b). Animals receiving Ad-RSV-β gal had β gal expression in both lung tissue and tumor nodules (c). Animals receiving Ad-OC-β gal expressed β gal only in tumors but not normal lung tissue (d). All tissue sections were photographed at high power. Figure 18. Therapeutic effect of Ad-OC-TK/ ACV. Animals bearing osteosarcoma lung metastases were treated with Ad-OC-TK/ ACV (a), PBS (b), Ad-OC-TK (c), or ACV (d) treatment as described above. Animals were sacrificed 25 days after tumor cell inoculation, and the lungs were removed for analysis. Note that fewer pulmonary metastatic nodules were found on the lung surface of animals with Ad-OC-TK/ ACV treatment (a) than in control animals with other treatments (b, c, d). Figure 19. Reduction of the number of pulmonary metastatic nodules with Ad-OC- TK/ ACV treatment. Animals bearing osteosarcoma lung metastases were treated with PBS, ACV, Ad-OC-TK, or Ad-OC-TK/ ACV as described above. Animals were sacrificed 25 days after tumor cell inoculation, and the lungs were removed for analysis. Animals receiving Ad-OC-TK/ ACV treatment had significantly fewer lung tumor nodules compared to animals with other treatments (p < 0.0001, t-test). There were no significant differences in the number of lung tumor nodules between receiving PBS, ACV, or Ad-OC-TK treatment. Figure 20. Reduction of the wet weight of lung carrying osteosarcoma tumor nodules with Ad-OC-TK/ AC treatment. Animals bearing osteosarcoma lung metastases were treated with PBS, ACV, Ad-OC-TK, or Ad-OC-TK/ACV as described above. Animals were sacrificed 25 days after tumor cell inoculation, and the lungs were removed for analysis. Animals receiving Ad-OC-TK/ACV treatment had significantly lighter lungs compared to those animals with other treatments (p= 0.0005, t-test). There were no significant differences in lung wet weight between animals receiving PBS, ACV, or Ad- OC-TK treatment. Figure 21. Tumor regression induced by Ad-OC-TK/ACV. Animals bearing osteosarcoma lung metastases were treated with PBS, ACV, Ad-OC-TK, or Ad-OC- TK/ACV as described in Materials and Methods. Animals were sacrificed 25 days after tumor cell inoculation, and the lungs were removed for analysis. All of the nude mice with PBS, ACV, and Ad-OC-TK treatment had massive pulmonary metastatic tumor nodules (panel a, with PBS), but Ad-OC-TK/ACV treated animals had smaller tumor nodules (panel b) and extensive necrotic lesions (indicated by arrow) in the tumors. Tissue sections were photographed at low power. Figure 22. Survival of animals receiving Ad-OC-TK/ACV treatment. Animals bearing osteosarcoma lung metastases were treated with PBS (6 animals), ACV (6 animals), Ad- OC-TK (6 animals), or Ad-OC-TK/ACV (8 animals) as described above. The survival study end-points were animal death or sacrifice per request by animal care personnel for distress, as evidenced by lethargy, ruffled fur or weight loss. Since there were no significant differences between 3 control groups, animals receiving PBS, ACV, or Ad-OC- TK, these data were combined as control animals in the Kaplan-Meier survival rate study. The survival rate of Ad-OC-TK/ACV treated animals was significantly prolonged (0.005 <p <0.01, generalized Wilcoxon test) when compared to the combined control animals. REFERENCES 1. Cheon J, Ko SC, Gardner TA, et al. Chemogene therapy for osteosarcoma: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Therapy. 1997; 4:359-365. 2. Bonnekoh B, Greenhalgh DA, Bundman DS, et al. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol. 1995; 104:313-317. 3. Eastham JA, Chen SH, Sehgal I, et al. Prostate cancer gene therapy: Heφes simplex virus thymidine kinase gene transduction followed by gancicrovir in mouse and human prostate cancer models. Human Gene Therapy. 1996; 7:515-523. 4. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Research. 1996; 56:4614-4619. 5. Treat J, Kaiser LR, Sterman DH, et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase I trial (BB-IND 6274). Human Gene Therapy. 1996; 7:2047-2057. 6. Eck SL, Alavi JB, Alavi A, et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Human Gene Therapy. 1996; 7: 1465-1482. 7. Lesoon-Wood LA, Kim WH, Kleinman HK, et al. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Human Gene Therapy. 1995; 6:395-405. 8. Vile RG, Nelson JA, Casteleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Research. 1994; 54:6228-6234 9. Brand K, Arnold W, Bartels T, et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Therapy. 1997; 4:9-16. 10. O'Reilly R. NCCN Pediatric osteosarcoma practice guidelines. Oncology. 1996; 10: 1799-1806. 11. Saeter G, Hoie J, Stenwig AE, et al. Systematic relapse of patents with osteogenic sarcoma: Prognostic factors for long term survival. Cancer. 1995; 75: 1084-1093. 12. Naka T, Fukuda T, Shinohara N, et al. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer. 1995; 76:972-984. 13. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: DeVita J, VT, Hellman S, Rosenberg SA eds. Cancer Principles and Practice of Oncology, Philadelphia: J. B. Lippincott Company; 1993; 1509-1566. 14. Ward W, Mikaelian K, Dorey F, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J. Clin. Oncol. 1994; 12: 1849-1858. 15. Ducy P, Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Molecular and Cellular Biology. 1995; 15:1858-1869. 16. Zhang WW, Fang X, D. BC, et al. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques. 1993; 15:868-872. 17. Graham FL, Provoke L. Methods for construction of adenovirus vectors. Mol. Biotech. 1995; 3:207-220. 18. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945; 1:80-83. 19. Zhu N, Liggitt D, Liu Y, et al. Systemic gene expression after intravenous DNA delivery into adult mice . Science . 1993 ; 261 : 209-211. 20. Thierry AR, Lunardi-Iskandar Y, Bryant JL, et al. Systemic gene therapy: biodistribution and long-term expression of a transgenic in mice. Proc. Natl. Acad. Sci. USA. 1995; 92:9742-9746. 21. Philip R, Liggitt D, Philip M, et al. In vivo gene delivery-efficient transfection of T-lymphocytes in adult mice. J. Biol. Chem. 1993; 268: 16087-16090. 22. Donahue HJ, Mcleod KJ, Rubin CT, et al. Cell-to-cell communication in osteoblastic networks: cell line-dependent hormonal regulation of gap junction function. Journal of bone and mineral research. 1995; 10:881-889. 23. Weksler B, Lenert J, Ng B, et al. Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model. J Thorac Cardiovasc Surg. 1994; 107:50-54.

Claims: CLAIMS: 1. A therapeutic agent Ad-OC-TK, comprising a recombinant adenovirus (Ad) vector containing an osteocalcin (OC) promoter for expression of toxic thymidine (TK) kinase. 2. The therapeutic agent of Claim 1, further containing acyclovir (ACV). 3. The therapeutic agent of Claim 1, further containing Vitamin D,. 4. A method for treating a tumor, comprising delivering to said tumor a therapeutic agent Ad-OC-TK, said therapeutic agent comprising (a) a recombinant adenovirus (Ad) vector containing an osteocalcin (OC) promoter driven toxic thymidine kinase, and (b) optionally acyclovir (ACV). 5. The method of Claim 3, wherein said tumor is osteosarcoma, breast cancer, prostate cancer, melanoma or brain tumor. 6. A method for preventing osseous metastatic tumor comprising delivering to said osseous metastatic tumor a therapeutic agent Ad-OC-TK, said therapeutic agent comprising (a) a recombinant adenovirus (Ad) vector containing an osteocalcin (OC) promoter driven toxic thymidine kinase (KT). 7. The method of Claim 5, wherein said osseous metastatic tumor is a melanoma, a breast cancer, a prostate cancer or a brain cancer. 8. A method of systemically treating an individual in need of the same with a therapeutic agent comprising a recombinant adenovirus vector containing an osteocalcin promoter for expression of toxic thymidine kinase (Ad-OC-TK) comprising administering said therapeutic agent in a pharmaceutically acceptable carrier to said individual intravascularly, in a pharmaceutically effective amount. 9. The method of claim 8, wherein said pharmaceutically effective amount is effective to treat a tumor. 10. The method of claim 9, wherein said tumor is a manifestation of a metastatic cancer. 11. The method of claim 10, wherein said metastatic cancer is osteosarcoma, breast cancer, prostate cancer, melanoma or brain tumor. 12. The method of claim 8, wherein said therapeutic agent is admimstered together with acyclovir. 13. A method of treating benign prostatic hypertrophy, comprising administering to an individual in need of same a pharmaceutically effective amount of Ad-OC-TK in a pharmaceutically acceptable carrier. 14. The method of claim 13, wherein said Ad-OC-TK is administered together with acyclovir. 15. The method of claim 13, wherein said Ad-OC-TK is administered intravascularly. 16. A method of treating arteriosclerosis, comprising administering to an individual in need of same a pharmaceutically effective amount of Ad-OC-TK. 17. The method of claim 16, wherein said Ad-OC-TK is administered, together with a pharmaceutically acceptable carrier, intravascularly.

Inventors: CHEON JUN, CHUNG LELAND W K, KAO CHINGHAI, KO SONG-CHU, SIKES ROBERT A, CHEON, JUN, CHUNG, LELAND, W., K., KAO, CHINGHAI, KO, SONG-CHU, SIKES, ROBERT, A.
Applicants: UNIV VIRGINIA, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Application year: 1998
Main classification: A61K35
IPC codes: A61K48, C12N15, C12P21